Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - GEN1047 for Solid Tumors - First in Human (FIH) Trial
Back

GEN1047 for Solid Tumors - First in Human (FIH) Trial

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

London Manchester London

Medical Conditions

Neoplasms
Ovarian Neoplasms
Endometrial Neoplasms
Breast Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this trial is to measure the following in participants with solid tumors who receive GEN1047:

* The side effects seen with GEN1047 * What the body does with GEN1047 once it is administered * What GEN1047 does to the body once it is administered * How well GEN1047 works against solid tumors

The estimated trial duration for an individual participant is 8 months, consisting of a 28-day screening period, an estimated 3 month treatment period (the duration of treatment may vary for each participant), and an estimated 4 month post-treatment follow-up period (the duration of follow-up may vary for each participant). All participants will receive active drug; no one will be given placebo.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Dec 2021 Dec 2025

INTERVENTIONAL

Intervention Type : BIOLOGICAL
Intervention Description : GEN1047 will be administered as an intravenous infusion. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial.

Intervention Arm Group : GEN1047;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • University College London Hospital
    London
    NW1 2BU
  • The Christie Hospital
    Manchester
    M20 4BX
  • St Bartholomews Hospital
    London
    EC1A7BE


The study is sponsored by Genmab



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05180474
Last updated 04 August 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top